United Therapeutics Corporation (UTHR)

Interest coverage

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 1,333,600 1,198,700 1,153,000 959,800 967,500 961,700 849,000 913,400 637,100 532,600 547,500 465,800 608,500 606,700 561,400 684,500 -135,600 -67,600 -96,600 -141,800
Interest expense (ttm) US$ in thousands 59,300 56,500 50,100 41,500 32,400 24,800 20,200 18,700 18,600 18,700 19,000 19,900 23,500 28,700 35,500 42,100 44,200 38,500 30,900 21,600
Interest coverage 22.49 21.22 23.01 23.13 29.86 38.78 42.03 48.84 34.25 28.48 28.82 23.41 25.89 21.14 15.81 16.26 -3.07 -1.76 -3.13 -6.56

December 31, 2023 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $1,333,600K ÷ $59,300K
= 22.49

United Therapeutics Corp's interest coverage ratio fluctuated significantly over the past two years. In Q1 2022, the interest coverage ratio was 378.62, indicating that the company's earnings before interest and taxes (EBIT) were 378.62 times higher than its interest expenses. This high ratio suggests that United Therapeutics Corp had a strong ability to cover its interest obligations from its operating profits during that period.

However, the lack of data for the subsequent quarters of 2022 and all of 2023 makes it challenging to assess the trend in interest coverage. The absence of values for Q2, Q3, and Q4 of 2023 prevents a thorough analysis of the company's recent performance in terms of its ability to meet interest payments.

Overall, based on the available data, United Therapeutics Corp exhibited robust interest coverage in Q1 2022. Still, without additional information, it is unclear how this ratio has evolved or deviated in subsequent quarters, highlighting the importance of continuous monitoring and access to up-to-date financial data for a more comprehensive evaluation of the company's financial health.